Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Wiley full text link Wiley Free PMC article
Full text links

Actions

Share

.2013 Nov;76(5):752-62.
doi: 10.1111/bcp.12080.

Predicted heart rate effect of inhaled PF-00610355, a long acting β-adrenoceptor agonist, in volunteers and patients with chronic obstructive pulmonary disease

Affiliations

Predicted heart rate effect of inhaled PF-00610355, a long acting β-adrenoceptor agonist, in volunteers and patients with chronic obstructive pulmonary disease

Paul Matthias Diderichsen et al. Br J Clin Pharmacol.2013 Nov.

Abstract

Aim: To assess the cardiovascular effects of a new inhaled long-acting β-adrenoceptor agonist PF-00610355 in COPD patients.

Methods: Thirteen thousand and sixty-two heart rate measurements collected in 10 clinical studies from 579 healthy volunteers, asthma and COPD patients were analyzed. The relationship between heart rate profiles and predicted plasma concentration profiles, patient status, demographics and concomitant medication was evaluated using non-linear mixed-effects models. The median heart rate increase in COPD patients for doses of PF-00610355 up to 280 μg once daily was simulated with the final pharmacokinetic/pharmacodynamic (PKPD) model.

Results: An Emax model accounting for delayed on-and off-set of the PF-00610355-induced change in heart rate was developed. The predicted potency in COPD patients was three-fold lower compared with healthy volunteers, while no difference in maximum drug effect was identified. Simulations suggested a maximum placebo-corrected increase of 2.7 (0.90-4.82) beats min(-1) in COPD patients for a PF-00610355 dose of 280 μg once daily, with 19% subjects experiencing a heart rate increase of more than 20 beats min(-1) compared with 8% in the placebo group.

Conclusions: This PKPD analysis supports the clinical observation that no relevant effects of PF-00610355 on heart rate in COPD patients should be expected for doses up to 280 μg once daily.

Keywords: PF-610355; PKPD; long-acting β2 agonist; nonmem; salmeterol; tachycardia.

© 2013 The Authors. British Journal of Clinical Pharmacology © 2013 The British Pharmacological Society.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean (95% CI) observed HRCFB for four different subpopulations in the analysis dataset. There is no overlap between the populations. Observations are binned into groups by dose (A) or predicted plasma concentration (B). The dashed lines show Emax functions fitted to the data.formula image, human volunteers;formula image, asthma;formula image, COPD;formula image, human volunteers, MIAT (Miat monodose inhaler, model 5)
Figure 2
Figure 2
Goodness of fit plot for the final HR model. Population (A) and individual (C) predictions are scattered evenly around the line of unity. Epsilon shrinkage is 35%. Conditional weighted residuals of heart rate predictions (CWRES)vs. time after first dose (B), and CWRES vs. time since last dose (E, truncated to 0–24 h for clarity). CWRES vs. population predicted PF-00610355 concentration (D). CWRES in COPD patients and healthy volunteers are shown in red and black, respectively, and solid lines show loess smooth curves
Figure 3
Figure 3
Visual predictive check of heart ratevs. dose (upper panels) based on 1000 datasets simulated using the PKPD model, corrected for model prediction and stratified by COPD status. The dark grey scatter and the solid lines show the observed data and the corresponding median and 95% percentile intervals. The light grey boxes indicate the 95% confidence interval of model-predicted median and 95% percentile intervals. Observed samples were sorted into six bins (lower panels) containing an approximately equal number of samples according to the administered dose
Figure 4
Figure 4
Black solid lines and grey area illustrates the median (between replicates) median and 95% percentile intervals within replicates maximum change in HR (A) and maximum absolute HR (B)vs. dose on day 43 in COPD patients. Error bars show the 95% percentile intervals of the medians between replicates. Dashed lines show 5, 10, and 20 beats min−1 change in HR (A) and 90, 100, and 110 beats min−1 absolute HR (B). Open circles show observed data
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Global initiative for Chronic Obstructive Lung Disease. Global Strategy for Diagnosis, Management, and Prevention of COPD. 2010. Available athttp://www.goldcopd.org/uploads/users/files/GOLDReport_April11%202011.pdf (last accessed 4 January 2012)
    1. Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) Eur Respir J. 1997;10:815–821. - PubMed
    1. Rossi A, Kristufek P, Levine BE, Thomson MH, Till D, Kottakis J, Della Cioppa G. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest. 2002;121:1058–1069. - PubMed
    1. Drugs@FDA. FDA Approved Drug Products: Indacaterol. Available athttp://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/index.cfm (last accessed 10 October 2011)
    1. EMA. European Medicines Agency – Onbrez Breezhaler. 2011. Available athttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medici... (last accessed 10 October 2011)

MeSH terms

Substances

Related information

LinkOut - more resources

Full text links
Wiley full text link Wiley Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp